{"product_id":"sarepta-business-model-canvas","title":"Sarepta Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare-disease RNA \u0026amp; gene-therapy Canvas: partnerships, regulatory revenue, high-margin pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSarepta Therapeutics's Business Model Canvas maps its rare-disease focus: differentiated RNA and gene therapies, strategic partnerships, regulatory-driven revenue, and high-margin specialty pricing. This concise snapshot reveals key risks and growth levers. Purchase the full Canvas for a complete, editable strategic playbook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with leading neuromuscular and genetic medicine institutes give Sarepta access to patient populations (Duchenne prevalence ~1:3,500–5,000 male births), biomarkers, and translational expertise. Joint studies accelerate target validation and trial enrollment, shortening timelines and lowering attrition. Data sharing and co-authorship amplify scientific credibility and publication impact. These alliances reduce early-stage risk and expand innovation throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized CDMOs supply GMP capacity, quality systems and tech-transfer for AAV, oligonucleotide and plasmid manufacturing at clinical and commercial scale, enabling Sarepta to accelerate SRP-9001 and oligo programs. Flexible outsourced capacity lowers Sarepta capex and shortens scale-up timelines, with the cell and gene CDMO market estimated at $6.3B in 2024. Dual-sourcing across geographies mitigates supply risk and supports global rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Foundations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with advocacy groups such as Parent Project Muscular Dystrophy, Muscular Dystrophy Association and Muscular Dystrophy UK bolster disease awareness and trial recruitment while providing real-world insights; Duchenne affects about 1 in 3,500–5,000 male births.\u003c\/p\u003e\n\u003cp\u003eJoint programs with these groups have shaped meaningful endpoints and patient support services, and advocacy validation is routinely used in payer and regulator dialogue.\u003c\/p\u003e\n\u003cp\u003eCo-created educational and monitoring resources improve adherence and facilitate outcomes tracking across post‑approval registries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Technology Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProactive engagement with regulators and HTA bodies enabled Sarepta to pursue accelerated pathways and manage post-marketing commitments, supporting commercial rollout after 2024 approvals and contributing to company revenue near $1.9 billion in 2024.\u003c\/p\u003e\n\u003cp\u003eEarly regulatory advice shaped trial design, CMC readiness, and enhanced safety monitoring, reducing time-to-market and informing payer negotiations.\u003c\/p\u003e\n\u003cp\u003eOutcomes frameworks and risk-sharing agreements across multiple European HTAs de-risk launches and harmonize access across geographies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory meetings: targeted early\u003c\/li\u003e\n\u003cli\u003eRevenue (2024): ~$1.9B\u003c\/li\u003e\n\u003cli\u003eOutcomes-based agreements: used for multi-country launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, Specialty Pharmacies, and Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers, specialty pharmacies, and distributors underpin Sarepta’s access strategy: value-based contracting and hub distribution maintain patient access and payer alignment for rare-disease therapies; specialty pharmacies coordinate benefits, logistics, and ongoing patient support; ex-US distributors expand market reach; data partnerships enable real-world outcomes measurement to support reimbursement durability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue-based contracts: align payment to outcomes\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacies: benefits, logistics, adherence\u003c\/li\u003e\n\u003cli\u003eEx-US distributors: market expansion\u003c\/li\u003e\n\u003cli\u003eData partners: outcomes-driven reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners cut gene therapy risk: CDMO \u003cstrong\u003e$6.3B\u003c\/strong\u003e, revenue \u003cstrong\u003e$1.9B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships supply patient access, translational expertise, manufacturing scale and payer\/advocacy alignment—reducing development risk and speeding commercialization. CDMOs enable GMP AAV\/oligo scale (cell \u0026amp; gene CDMO market ~$6.3B in 2024). Advocacy and payer ties support enrollment, endpoints and value-based access; company revenue ~ $1.9B in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner type\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/Clinics\u003c\/td\u003e\n\u003ctd\u003eTrials, biomarkers\u003c\/td\u003e\n\u003ctd\u003eDuchenne ~1:3,500–5,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eGMP scale\u003c\/td\u003e\n\u003ctd\u003e$6.3B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\/Payers\u003c\/td\u003e\n\u003ctd\u003eAccess, endpoints\u003c\/td\u003e\n\u003ctd\u003eRevenue ~$1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Sarepta Therapeutics outlining customer segments (patients, payors, clinicians), channels (specialty clinics, rare-disease networks), and value propositions (novel gene\/RNA therapies for Duchenne and rare neuromuscular diseases). It maps key partners, manufacturing and regulatory capabilities, revenue model (high-value therapeutics, partnerships, royalties), plus competitive advantages, risks, and go-to-market strategies for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Sarepta Therapeutics’ business model with editable cells, highlighting how gene therapy innovation, regulatory strategy, and payer access relieve patient and payer pain points in neuromuscular disease treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Genetic R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and optimization of RNA-targeted, gene therapy and gene editing programs drive Sarepta’s pipeline expansion, building on three FDA-approved DMD therapies to date. Rigorous preclinical efficacy and safety studies de-risk candidates ahead of INDs and clinical entry. Biomarker development (including dystrophin quantification assays) underpins precise patient selection. Continuous IP filing strategy secures platform advances and freedom to operate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development and Evidence Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase 1–4 trials validate safety, efficacy and durability across diverse DMD subpopulations, enrolling cohorts from dozens to hundreds per study; DMD affects ~1 in 3,500–5,000 male births. Natural history and registry studies spanning 50+ countries inform endpoints and comparator baselines. Real-world evidence underpins label expansions and payer decisions while long-term follow-up monitors evolving benefit‑risk profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC and Manufacturing Scale-Up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcess development at Sarepta focuses on consistent, high-titer vector and oligonucleotide output to meet therapy needs; Duchenne muscular dystrophy prevalence is about 1 in 3,500–5,000 male births (2024), informing demand estimates. Tech transfer and validation enable reliable commercial supply across sites. In-process controls safeguard critical quality attributes. Capacity planning aligns production with global demand scenarios and clinical rollout timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, Market Access, and Pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory, market access, and pharmacovigilance activities target global filings that leverage expedited pathways and orphan incentives to accelerate patient access for rare neuromuscular therapies.\u003c\/p\u003e\n\u003cp\u003eHealth economic models and HTA dossiers quantify value and support price and reimbursement negotiations across major markets.\u003c\/p\u003e\n\u003cp\u003eRobust safety surveillance systems enable continuous risk management, signal detection, and fulfillment of post-marketing commitments and registry obligations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpedited designations and orphan benefits targeted\u003c\/li\u003e\n\u003cli\u003eHEOR models drive value dossiers for payers\u003c\/li\u003e\n\u003cli\u003eSafety surveillance for real-time signal detection\u003c\/li\u003e\n\u003cli\u003ePost-marketing studies and registries ensure compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Medical Affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSpecialty field teams educate prescribers and centers of excellence to support uptake of therapies such as Exondys 51 (approved 2016) and Amondys 45 (approved 2021); medical affairs disseminates peer-reviewed data and engages KOLs to drive evidence adoption. Patient services coordinate access, adherence, and financial support while launch execution aligns activities to targeted geographies and payer landscapes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField coverage: focused on centers of excellence\u003c\/li\u003e\n\u003cli\u003eMedical affairs: peer-reviewed publications and KOL engagement\u003c\/li\u003e\n\u003cli\u003ePatient services: access, adherence, financial navigation\u003c\/li\u003e\n\u003cli\u003eLaunch: geography-aligned execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnd-to-end DMD RNA\/gene therapy pipeline: trials to launch for \u003cstrong\u003e15,000–20,000\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/optimization of RNA, gene therapy and gene editing programs; rigorous preclinical and Phase 1–4 trials across DMD subtypes; manufacturing scale‑up, tech transfer and QA to meet estimated addressable DMD population ~15,000–20,000 males globally; regulatory\/HEOR, safety surveillance, specialty field teams and patient services to enable launch and access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKPI\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003eActive studies\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e3–5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eAddressable\u003c\/td\u003e\n\u003ctd\u003e15k–20k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Sarepta Therapeutics Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample, and reflects the full structure and content you’ll receive after purchase. Upon ordering you’ll get this exact file in editable Word and Excel formats, complete with all sections populated and formatted. No surprises—what you see is the file you’ll download, ready to present, edit, and share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674920239481,"sku":"sarepta-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/sarepta-business-model-canvas.png?v=1755798593","url":"https:\/\/portersfiveforce.com\/products\/sarepta-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}